CMTA and Pharnext Enter Biomarker Research Collaboration

…is currently no treatment available.” About Pharnext Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments….

CMTA-STAR Biotech & Alliance Partners

…the Integrated Stress Response (ISR) for the treatment of a broad range of diseases. The company plans to demonstrate the clinical effectiveness of its drug candidate IFB-088 for the treatment

Medication Study

…category placement of some agents. As with any treatment, the risk of neuropathy exacerbation must be weighed against expected treatment benefits and available equivalent, alternative treatments. Despite the limitations of…

CMT2A Research

…disease-specific CRISPR reagents can prevent disease pathology in a rodent model of CMT2A. PROJECT GOAL: EARLY PHASE TREATMENT TRIALS OF CMT2A Grant Amount: $18,942 Principal Investigator: Michael Shy, MD, University…

Coronavirus (COVID-19) and CMT

…impacts will the vaccine have on possible future gene therapy treatments or medications? Whether the vaccine will have an adverse impact on any course of treatment that you or your…